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ABSTRACT

Compounds of the class of 4-oxo-butenoic acid derivatives
are disclosed along with the surprising use property of these
compounds as a anti-tumor agents in humans against breast
carcinoma, which include: 2-(N'-Fluoren-9-ylidenehydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl
ester (OF-06), l-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-4me thy 1-benzoy 1)-5-oxo-2,5-dihydro- lH-pyrrole-2carboxylic acid methyl ester (lF-07), 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid (3F10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15),
and 4,4-Dihydroxy-5-4-methyl-benzoyl)-2-phenyl-2,4dihydro-pyrazol-3-one (3F-16) as well as some novel
derivatives of these compounds claimed (see Table 2). The
invention also encompasses a class of the compounds with
the novel property of anti-tumor activity against human
breast cancer, which includes the following compounds
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N'-[1(4-Chloro-phenyl)-ethylidene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester (OF-20); 2-(N'-Fluoren-9ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl
ester (lF-04); and 4-Chloro-4-( 4-ethoxy-phenyl)-2(fiuoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
ester (3F-19).
2 Claims, 2 Drawing Sheets
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Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
admixture containing crotonic acid for treating tumors
(see Abstract);
This is a Divisional of application Ser. No. 10/164,541
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
filed Jun. 7, 2002 now U.S. Pat. No. 6,602,907.
4-oxo-2-butenoic acid derivatives (column 13, lines
5
FIELD OF THE INVENTION
21-59; also in columns 15+, examples 25,26,32,34,40,
43-46,77-79,97,99,103,106,), which are useful for
This invention relates to novel 4oxo-butenoic acid derivainhibiting colorectal cancer, i.e., colon cancer
tives and to the use of these compounds and related com(Abstract); and,
pounds with novel biological activity in humans as therapeutic means for the prevention and treatment of the human 10
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxobreast cancer and claims the benefit of priority of U.S.
2-butenoic acid derivatives said to be useful for treatProvisional Application Serial No. 60/296,823 filed Jun. 8,
ment of AIDS (column 1, line 8 and column 2, line 61;
2001.
and,
Yonemeto,
et al (U.S. Pat. No. 6,083,985) recites a
BACKGROUND OF THE INVENTION
number of anti-tumor or anti-AIDS agents that include
15
Cancer is a global killer of humans with breast cancer
butenoic acid derivatives.
among the leaders of killing humans yearly. Breast cancer is
The U.S. patent literature gas many disclosures of
the primary killer of women. One in eight American women
butanoic acid derivatives including:
will develop breast cancer in her lifetime. In 2001, an
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
estimated 192,700 women in the U.S. will be diagnosed with
anti-inflammatory and analgesic compounds, including
invasive breast cancer and 42,600 with in situ (tumors 20
adenocarcinoma (column 1, line 55), which includes
contained in the milk ducts). An estimated 40,000 will die
heterocyclic alcohol-esters (column 11, lines 1-16) and
from the disease.
butanoic acid derivatives (many Examples including 47
An estimated 3 million women in the U.S. today are living
through 162);
with breast cancer of TREATMENT OF BREAST CANGirard,
et al (U.S. Pat. No. 5,308,852) discloses many
CER which 2 million have been diagnosed with the disease 25
compounds including butanoic acid derivatives (see
and 1 million have the disease but do not yet know it.
Methods B and C of schemes II and III) which comThe incidence of breast cancer in the U.S. has more than
pounds which are said to inhibit tumor metastasis
doubled in the past 30 years. In 1964, the lifetime risk was
(column 7, line 56 and column 8, line 4); and,
1 in 20. Today it's 1 in 8. Breast cancer is the most
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat.
commonly diagnosed cancer in women in both America and 30
No. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
worldwide. Breast cancer rates are the highest in industridescribe 148 benzoxazine and pyrido-oxazine heteroalized countries. It is estimated that 1.2 million new diagcyclics as anti-bacterial compounds.
noses and 500,000 deaths from breast cancer will occur
It appears from the foregoing that the derivatives of
worldwide this year. Further, it appears that breast cancer is
4-oxo-butanoic acid of interest are not disclosed and thus
the leading cause of death for American women of ages 25 35
there is no report of their activity against human breast
to 55 years.
cancer.
No vaccine or other universally successful method for the
Consequently, there is a need for an anti-cancer drug for
prevention or treatment of breast cancer is currently availhumans that mitigates the above mentioned disadvantages of
able. Management of the disease currently relies on a
current drug therapy and effectiveness against human breast
combination of early diagnosis (through routine breast 40 cancer.
screening procedures) and aggressive treatment, which may
include one or more of a variety of treatments such as
SUMMARY OF THE INVENTION
surgery, radiotherapy, chemotherapy and hormone therapy.
The first objective of the present invention is to provide a
The course of treatment for a particular breast cancer is often
selected based on a variety of prognostic parameters, includ- 45 drug effective for treatment of human breast cancer.
ing an analysis of specific tumor markers. {Porter-Jordan
Another object of this invention is to provide novel
and Lippman, Breast Cancer 8:73-100 (1994)}. However,
4-oxo-butenoic acid derivatives.
the use of established markers often leads to a result that is
A further object of this invention is to provide 4-oxodifficult to interpret, and the high mortality observed in
butenoic acid derivatives with novel activity against human
breast cancer patients indicates that improvements are
breast cancer.
needed in the treatment, diagnosis and prevention of the 50
A preferred embodiment of the invention encompasses a
disease.
class of compounds having the property of anti-tumor activAccordingly, there is a need for improved methods for
ity against human breast cancer comprising the novel strucchemotherapy for breast cancer. The present invention fultures of 4-oxo-butenoic derivatives and more specifically
fills this need and further provides other related advantages.
those derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5The U.S. patent literature has many disclosures of oxo- 55 dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06);
butenoic ( crotonic) acid derivatives:
1-(2,4-Dimethy 1-pheny 1)-2,4-dihydroxy-3-( 4-methy lPamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
benzoyl)-5-oxo-2,5-dihydro-lH-pyrrole-2-carboxylic acid
derivatives (column 22, lines 43-58) for the treatment
methyl ester (lF-07); 4-(4-Methoxy-phenyl)-2,4dioxo-3of colonic polyps;
(phenyl-hydrazono )-butyric acid (3F-10); 4-( 4-ChloroJones et al (U.S. Pat. No. 6,121,450) discloses crotonic 60 phenyl)-2,4dioxo-3-(phenyl-hydrazono )-butyric acid ethyl
ester (3F-11 ); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro4acid derivatives (column 8, tine 34; column 78, line 24
methoxy-phenyl)-but-2-enoic acid (3F-15); and 4,4and at example 34 as steroid modifiers in treating breast
Dihydroxy-5-( 4-methy 1-benzoy1)-2-pheny1-2,4-dihydrocancer (column 1, lines 55-58);
pyrazol-3-one (3F-16) as well as novel derivatives of these
Kalden, et al (U.S. Pat. No. 5,334,612) discloses compounds said to be useful for treating AIDS including 65 compounds (see Table 2).
derivatives of carboxylic acid (column 9, line 31) and
The use of the following compounds for humans as
pyrrolidine (column 7, line 24);
therapeutic means for the eradication of human breast cancer

TREATMENT OF BREAST CANCER
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further encompasses the following: 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren -9-y lide ne-hydrazino )2-h ydro xy-4-o xo-butyric
acid methyl ester (OF-13); 2-{N'-[1-( 4Chloro-phenyl)ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)- 5
4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-e thoxy-pheny 1)-2-fi uoren-9-y lidenehydrazono )-but-3-enoic acid methyl ester (3F-19).
Further objects and advantages of this invention will be
apparent from the following detailed description of presently 10
preferred embodiments, which are illustrated structurally in
the accompanying drawings.

the compound designated as lF-07 is 1-(2,4-Dimethylphenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,
5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester;
the compound designated as 3F-10 is 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid
the compound designated as 3F-11 is 4-(4-Chlorophenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid
ethyl ester,
the compound designated as 3F-15 is 2-Hydroxy-4-oxo4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic
acid and,
the compound designated as 3F-16 is 4,4-Dihydroxy-5BRIEF DESCRIPTION OF THE FIGURES
( 4-methyl-benzoy 1)-2-pheny1-2,4-dihydro-pyrazol-3one.
15
FIG. 1 illustrates structurally a chemical compound desThese compounds have very high activity against human
ignated as OF-06.
breast cancer and a very low toxicity as Lethal Dose 50
FIG. 2 illustrates structurally a chemical compound des(LD 50) in animals. The percent activity and animal toxicity
ignated as lF-07.
for each compound is as follows:
FIG. 3 illustrates structurally a chemical compound des- 20
OF-06 (100% against human breast carcmoma and
ignated as 3F-10.
LD 50 >3000 mg/kg);
FIG. 4 illustrates structurally a chemical compound deslF-07 (100% against human breast carcmoma and
ignated as 3F-11.
LD 50 >500 mg/kg);
FIG. 5 illustrates structurally a chemical compound des3F-10 (100% against human breast carcmoma and
25
ignated as 3F-15.
LD 50 <750 mg/kg);
FIG. 6 illustrates structurally a chemical compound des3F-11 (100% against human breast carcmoma and
ignated as 3F-16.
LD 50 >2000 mg/kg);
3F-15
(100% against human breast carcmoma and
DESCRIPTION OF THE PREFERRED
LD
>200 mg/kg); and,
30
50
EMBODIMENTS
3F-16 (100% against human breast carcmoma and
Before explaining the disclosed-embodiments of the
LD 50 >500 mg/kg).
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the
PREPARATION OF (OF-06)
particular arrangement shown since the invention is capable 35
EXAMPLE 1
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-5,
As earlier recited this application has been filed in order
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A
to disclose: new 4-oxo-butenoic acids that have been found
solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethylto have high activity against human breast cancer and low 40 4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was
toxicity in animals.
previously published by E. Royals. JAm.Chem.Soc., 1945,
More specifically this application is for the novel anti67, 1508) and 3.88 g (0.02 moles) of fiuoren-9-ylidenetumor compounds OF-06, lF-07, 3F-10, 3F-11, 3F-15 and
hydrazine (2) in 80 mL of absolute toluene was refluxed for
3F-16 which have been structurally shown in FIGS. 1-6,
3 hr 30 min with a Dean-Stark trap (control for the end of
respectively, as well as novel derivatives of these com- 45 the reaction was carried by TLC). The solution was cooled
pounds claimed (see Table 2) and the activity against human
and the precipitate was filtered and recrystallized from
breast cancer of compounds OF-13, OF-20, lF-04, and
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of
3F-19 also as shown in Table 1 along with anti-tumor
yellow crystals, mp 135-137° C.
activity and toxicity.
Solubility: highly soluble in DMSO, DMFA,
50
To facilitate a full understanding of the invention:
dichloroethane, acetonitrile, slightly soluble in ethanol,
tetrachloromethane, insoluble in hexane and water.
the compound designated as OF-06 is 2-(N'-Fluoren-9y lidene-hydrazino )-5,5-dimethy1-4-oxo-hex-2-enoic
The synthesis of OF-06 is an example of well known
acid methyl ester,
amination/dehydration reactions.

CH3

I
I
CH3

CH3-C-CO-CH=C-COOCH3

+

I
OH

2
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-continued
CH3

CH3

I
I

I
I
N

CH3

NH

~

I
I

CH3-C-CO-CH2-C-COOCH3

CH3-C-CO-CH=C-COOCH3

-

II
I

CH3

N

~

lJL---V

B

A

OF-06

PREPARATION OF (lF-07)
EXAMPLE 2
The preparation of 1-(2,4-Dimethyl-phenyl)-2,4dihydroxy-3-( 4-methy 1-benzoy1)-5-oxo-2,5-dihydro-lHpyrrole-2-carboxylic acid methyl ester (lF-07). To a solution
of 1.65 g (0.0051 moles) of 2-(2,4-dimethyl-phenylamino)4-oxo-4-p-tolyl-but-2-enoic acid methyl ester (1) in 20 mL
of anhydrous chloroform was added 0.68 g (0.0054 moles)
oxalyl chloride. After refluxing for 30 min, 10 mL of
anhydrous hexane was added and 15 ml of solvent was
distilled out. The remainder of the solvent was evaporated
by keeping the flask open for 12 hr. The resulting precipitate
was filtered and recrystallized from dichloroethanetetrachlorometane (1:2) to give 1.25 g (62%) of compound
lF-7 in the form of white crystals, mp 133-135 ° C.
(decamp.)
Solubility: highly soluble in DMSO, acetonitrile, slightly
soluble in dichloroethane, benzene, insoluble in hexane
tetrachloromethane and water.

20

25

solution of 0.075 moles of 2-Hydroxy-4-( 4-methoxyphenyl)-4-oxo-but-2-enoic acid in 300 ml of dioxane small
potions of an aqueous solution prepared from 0.075 moles of
aniline, 0.92 moles of sodium nitrate and 19 ml of concentrated HCl in 90 ml of water (DI) was added. During cooling
11.4 g of sodium acetate was added and the reaction was
kept at the r.t. for 24 hr. Then 2 L of water was added to the
reaction mixture and the resulting precipitate was filtrated
and recrystallized from 1: 1 mixture of dimethyl chloride/
ethyl acetate to give 15.93 g of yellow crystals (60% yield)
with m.p. of 176-177 (decamp).

30

Solubility: highly soluble in DMSO, DMFA, slightly
soluble in chloroform, dichloroethane; insoluble in hexanes.

3 5 H 3C O - o - C O - C H = 1 - C O O H +
OH

H3C~COOCH3

1. (COCl)2,t
2. H10

n,c'¢
0

40

NH

2

H3co-O-co-IT-co-cooH
N-NHC6Hs

45
3F-10
CH3

50

PREPARATION OF (3F-11)

EXAMPLE 4

60
IF-7

PREPARATION OF (3F-10)
EXAMPLE 3
The preparation of 4-( 4-Methoxy-phenyl)-2,4dioxo-3(phenyl-hydrazono)-butyric acid (3F-10). To a hot stirred

65

The preparation of 4-( 4-Chloro-phenyl)-2,4-dioxo-3(phenyl-hydrazono)-butyric acid ethyl ester (3F-11). A solution of 0.5 g (0.0016 moles) of 5-(4-Chloro-benzoyl)-2phenyl-2H-pyrazole-3,4-dione (1) (synthesis was previously
published by Pimenova, E. V.; Andreichikov, Yu. S. (1992)
Zh. Org. Khim. 28, 376-89). in 2 mL of anhydrous ethanol
was refluxed for 1 hr. The resulting solution was cooled and
the precipitate was filtered to give 0.48 g (85% yield) of
yellow crystals with m.p. of 141-142° C. (decamp).

US 6,713,503 Bl
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PREPARATION OF (3F-16)
EXAMPLE 7
The preparation of 4,4-Dihydroxy-5-(4-methyl-benzoyl)5 2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16). A solution of
0.5 g (0.0017moles) of 5-( 4-Methyl-benzoyl)2-phenyl-2Hpyrazole-3,4-dione (1) (synthesis was previously published
by Pimenova, E. V.; Andreichikov, Yu S. (1992) Zh. Org.
Khim. 28, 376-89), and 5 mL of water (DI) was kept at the
10 rt until the solution became colorless and precipitate was
formed. The precipitate was filtered and recrystallized from
dichloroethane-water (10:1) to give 0.45 g (85%) of yellowbrown crystals, mp 134-135. 0 C.

3F-11

20

PREPARATION OF (3F-15)
EXAMPLE 6
The preparation of 2-Hydroxy-4-oxo-4-(2,3,5,6tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15). A 25
solution of sodium methoxide was prepared from 0.46 g
(20mmol) of sodium and 30 mL of absolute methanol by
addding small portions to a mixture of 6.35 g (10 mmol) of
1-pentafiuorophenyl-ethanone 1 and 3.54 g (10 mmol) of
dimethyl oxalate 2. After stirring the reaction for 24 hr at rt, 30
50 mL of 25% aqueous solution of HCl was added. The
resulting mixture was extracted with ether (240 mL),
washed by solution of brine and dried over anhydrous
Solubility: highly soluble in DMSO, dioxane, insoluble in
Na 2 S0 4 . The solvent was removed in vacuum and 10 mL of
35 water.
saturated solution of NaOH in ethanol was added with
PREPARATION OF (OF-13)
stirring. After 1 hr the reaction mixture was diluted with
water and acidified with H 2 S0 4 (10%) to obtain pH of 1-2.
EXAMPLE 8
The resulting precipitate of 3F-15 was filtered and recrysThe
preparation
of
4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9tallized from toluene to give 1.73 g (81 % yield) in the form
40 ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
of white-yellow crystals, mp 155-156° C. (decamp.).
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
) HCl
C6 F5-CO-CH3 + (COOCH3)2
3.88
g (0.02 moles) of fiuorene-9-ylidene-hydrazine (2) in
2
80 mL of absolute benzene and absolute toluene (1:1) was
2
3) NaOH/C2HsOH
45 refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
F
F
the reaction was determined by TLC), cooled and the
precipitate was filtered and recrystallized from benzenediethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
H 3 C O * j CO-CH=1-COOH
yield) of colorless crystals with mp 114-116° C.
OH
50
Solubility: highly soluble in DMSO, DMFA,
F
F
dichloroethane, acetonitrile, insoluble in hexane. The compound is not stable in solutions arid decomposes quickly
3F-15
when the solution is heated or stored for a long time with the
formation of OF-12.

+

2

US 6,713,503 Bl
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OF-13

OF-12

It is seen from the above that (OF-13) is an intermediate
product during the synthesis of (OF-12).

methyl ester (OF-12) (synthesis was previously published by
Konyukhova, N. A.; Krasnykh, 0. P.; Aliev, Z. G.;
Maslivets, A. N. Cehmistry ofHetorcyclic Compounds (New
PREPARATION OF (3F-19)
York, N.Y., United States) (Translation of Khimiya
Geterotsiklicheskikh Soedineii) (2001), 37(6), 779-780) in
EXAMPLE 9
5
mL of anhydrous benzene 0.3935 g (0.0031 moles) oxalyl
35
The preparation of 4 Chloro 4 (4 ethoxy phenyl) 2 (fiuoren
chloride was added. The reaction mixture was refluxed for 1
9 ylidene hydrazono) but 3 enoic acid methyl ester (3f-19)
hour 40 min, cooled, precipitate was filtered and recrystalto the solution of 10 g (0.0026 moles of 4 (4 Ethoxy phenyl)
lized from absolute benzene to give 0.62 g (54%) of yellow
2 (N' fiuoren 9 ylidene hydrazine) 4-oxo-but-2-enoic acid
crystals, m.p. 163-163 (decom).
30

C2H50--o-CO-CH2-w-coocH3

C2H50--o-CO-CH=1-coocH3
/NH

/N

N

N

~

lJ-----JU

~

lJ-----JU

OF-12

H5C20--0-1=CH2-w-COOCH3
Cl

/N

N

~

lJL----lJ
3F-19
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TABLE 1
Some Compounds of the Invention

Activity
(ATCC
#

OF-13

Structure

Name

OH

C2HsO~COOMe
0

NH,

4-( 4-Ethoxy-phenyl)2-(N'-fluoren-9ylidene-hydrazino )-2hydroxy-4-oxo-butyric
acid methyl ester

HrB123)

LDsa,

mg/kg Reference

100%

>1500 Miles et. al.
UCF-303A

>250 Miles et. al.
UCF-311C

N

~

V----V
OF-20

2-{N'-[1-( 4-Chlorophenyl)-ethylidene ]hydrazino }-4-oxo-4phenyl-but-2-enoic
acid methyl ester

83%

lF-04

2-(N'-Fluoren-9ylidene-hydrazino )-4oxo-4-phenyl-but-2enoic acid methyl ester

93%

Maslivets, Andrej N.;
Krasnykh, Olga P.;
Aleksandrova, Galina A.;
Vozhakova, Alla V. Russ. (1993),

CODEN: RUXXE7 RU 2003655 Cl
19931130 Application: RU 91-5013322
19910704.

/NH

0

>1000 Andrejchikov, Yurij S.;

N

oQ)
3F-19

4-Chloro-4-( 4-ethoxyphenyl)-2-(fluoren-9ylidene-hydrazono)but-3-enoic acid

methyl ester

100%

>200 Konyukhova, N. A.;
Krasnykh, 0. P.;
Aliev, Z. G.;
Maslivets, A. N.
Chemistry of Heterocyclic Compounds
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TABLE 2

Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

OCH3

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenylbutyric acid methyl ester

0

I
N....,_
NH

¢
Cl

2

OCH3

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-p-tolylbutyric acid methyl ester

0

I
N....,_
NH

¢
Cl

OCH3

3

2,4-Dioxo-4-p-tolyl-3-(p-tolyl-hydrazono)-butyric acid
methyl ester

0

4

OCH3 3-[ (4-Chloro-phenyl)-hydrazono ]-4-( 4-methoxy-phenyl)2,4-dioxo-butyric acid methyl ester

0

I
N
'NH

¢
Cl
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Structure

Name
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OCH3

0

I
N'-.

Cl

4-(4-Chloro-phenyl)-2,4-dioxo-3-(p-tolyl-hydrazono)butyric acid methyl ester

NH

¢
OCH3

4-(4-Chloro-phenyl)-3-[ (4-methoxy-phenyl)-hydrazono ]2,4-dioxo-butyric acid methyl ester

0

Cl

OC 2H5

7

4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)butyric acid ethyl ester

0

Cl

8

oc2H5

0

2,4-Dioxo-3-(phenyl-hydrazono )-4-p-tolyl-butyric acid
ethyl ester
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Structure

9

2,4-Dioxo-4-phenyl-3-(phenyl-hydrazono )-butyric acid
methyl ester

0

I
N'-.

NH

6

10

OCH3

0

I
N'-.

NH

6

11

OCH3

4-(4-Bromo-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)butyric acid methyl ester

0

I
N'-.

Br

12

2,4-Dioxo-3-(phenyl-hydrazono )-4-p-tolyl-butyric acid
methyl ester

NH

6
OCH3 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid methyl ester

0

I
N'-.

NH

6
13

OCH3 4-(4-Ethoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid methyl ester

0

I
N'-.

NH

6
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#

Structure
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OCH3

0
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NH
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6
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OCH3

4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)butyric acid methyl ester

0

I
N....._
NH

Cl

16

4-(4-Fluoro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)butyric acid methyl ester

6

3-[ (4-Methoxy-phenyl)-hydrazono ]-2,4-dioxo-4-phenylbutyric acid methyl ester

0

I
N....._
NH

¢
OCH3

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenylbutyric acid methyl ester

17

0

I
N....._
NH

¢
Cl

CYTOTOXICITY ASSAY
The activity in human breast cancer of the novel compounds (as earlier reported) was realized by the following
procedure which determines the inhibitory effect of test
samples on the growth of human breast cancer cells.
(ATCC HTB123) The HTB123 cells are grown in RPMI
1640 media+10% Fetal bovine serum+4.5g/L glucose+lO
mM HEPES+ 1.0 mM sodium pyruvate+ 1% Antibiotic/

60

65

Antimycotic for approximately 48 hours at 37° C./5% C0 2
in the presence of the test compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-(4,5-dimethy lthiazo 1-2-y1)-5-( 3-carboxymethoxyphen yl)-2-( 4-sulfophenyl)-2H-tetrazolium, inner salt) is an aqueous compound that is reduced to soluble formazan by the
presence of NADH formed by dehydrogenases present
within the HTB123 cells. The absorbance of the formazan
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can be measured at 490 nm and is directly proportional to the
number of living cells present in the culture. PMS
(Phenazine Methosulfate) is added an electron coupling
reagent and greatly increases the rate of reduction.
To facilitate a full understanding of the procedure the
following definitions are offered:
Test wells-wells containing test sample and Diluted
HTB123 cells
Test values-absorbance of test wells
Blank wells-wells containing test sample and HTB123
media (HHTB2-01S); used to obtain background
absorbance due to test sample
Blank values-absorbance of blank wells
Negative Control-maximal cell growth; results of test
samples will be expressed as a percent of the Negative
Control
Positive Control-known inhibitor of HTB123 cells; used
to validate assay system
Matrix-solvent that the samples are prepared/diluted in
Assay samples of similar origin and matrix (e.g., methanol extraction, methylene chloride extraction, water soluble
samples, etc.) together on the same plate in order to reduce
the number of steps performed per plate.
Blank values will be determined for each sample to
account for any color contribution due to the sample itself.
These blank wells must contain the same amount of sample
plus HTB123 media (no cells). After completion of MTS/
PMS reaction blank values will be subtracted from the test
value to obtain a net absorbance that will be used to calculate
cell density.
All results are based upon a comparison to the Negative
Control value of the plate. The Negative Control must
contain the same amount of matrix (e.g., solvent) to offset
any destructive effect the matrix may have on the growth of
the HTB123 cells (allows for baseline values to be set).
For most samples, a HTB123 cell growth (diluted two to
four-fold, depending upon the appearance of the inoculum*)
of approximately 48 hours followed by and incubation of 3
hours with the MTS/PMS Reagent is optimal.

2-(N'-Fluoren-9-y lidene-hydrazino )-5,5-diethy1-4-oxo-hex2-e noic acid methyl ester (OF-06); 1-(2,4-Dimethylphenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,5dihydro-lH-pyrrole-2-carboxylic acid methyl ester (lF-07);
4-( 4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid (3F-10); 4( 4-Chloro-phenyl)-2,4-dioxo-3(phenyl-hydrazono)-butyric acid ethyl ester (3F-11);
2-Hydroxy4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)but-2-enoic acid (3F-15) and, 4,4-Dihydroxy-5-( 4-methylbenzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16), as
well as all novel derivatives of these compounds claimed
(see Table 2), and the additional compounds of Table 1 with
activity against human breast cancer which include the
following compounds 4-(4-Ethoxy-phenyl)-2-(N'-fiuoren-9ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid methyl
ester (OF-13); 2-{N-[1-( 4-Chloro-phenyl)-ethylidene ]hydrazino }-4-oxo-4-phenyl-but-2-enoic acid methyl ester
(OF-20); 2-N'-Fluoren-9-ylidene-hydrazino )-4-oxo-4phenyl-but-2-enoic acid methyl ester (lF-04); and 4Chloro4-( 4-ethoxy-phen y1)-2-(fiuoren-9-y lidene-hydrazono )-but3-enoic acid methyl ester (3F-19).
All the compounds are unique in the in vitro treatment of
humans and can be used as therapeutic means for the
eradication of tumors from the human breast in a pharmaceutical composition comprising a non-toxic effective
amount of the referenced compound or a tautomeric form
thereof or a pharmaceutically acceptable salt thereof or
pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier thereof.
For administration to man in the curative or prophylactic
treatment of human breast cancer in vitro dosages of compounds of the invention will generally be in the range of
from 5 to 500 mg daily for an average adult patient (70 kg).
Thus for a typical adult patient, individual tablets or capsules
contain from 2-500 mg of active compound, in a suitable
pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per
day. Dosages for intraveneous, buccal or sublingual administration will typically be within the range of from 5-1000
mg per single dose as required. In practice the physician will
determine the actual dosing regimen which will be most
suitable for an individual patient and it will vary with the
age, weight and response of the particular patient The above
dosages are exemplary of the average case but there can be
individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
invention.
The maximum human non-toxic one time administration
dose for the compound(s) of the invention appears to range
from 100 to 1500 mg.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
The invention thus provides a method for the treatment of
breast carcinoma in a human mammal which comprises
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*Due to the nature of the HrB123 cells it is very difficult to obtain accurate
cell densities. Continuation of the HrB123 cell line typically consists of the 40
dilution of mature cells at two or three-fold into fresh media and growth at
37° C./5% C0 2 for two to three days.

In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should not
decrease the net absorbance to less than 90% of the Negative
Control (HTB123 cells are somewhat resistant to methotrexate) is utilized.

45

ANIMAL TOXCITY BIOASSAY
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperitoneal injection of 2% solution of tested compound in starch
(the compound was dissolved in starch slime and injected)
on the basis of 0.1 ml of solution per 10 g of the animal
weight. Each dose was tested on the group of 6 animals that
were observed during 14 days period. (This method was
approved by the Pharmacology committee of Russian Ministry of Health and has been widely used since 1968.)
Averaged lethal dose (LD 50 ) of the compound was computed using results of experiments on 5-7 groups of animals
using method of Litchfield and Wilkinson. (Belenkii M. L.
"Elements of quantative determination of the pharmacological effect," Leningrad, 1963, 71 pages).
USE OF THE INVENTION FOR TREATMENT
OF HUMAN BREAST CANCER
The compounds of the invention, i.e. 4oxo-butenoic acids
derivatives and more specifically those novel derivatives:
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administering an effective, non-toxic, amount of a heterocyclic compound according to the invention or a tautomeric
form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate
thereof, to abreast carcinoma invaded human mammal in 5
need thereof.

24
the life of many people, it is not a cure, and many patients
develop resistance to it. Many tumor types show minimal or
no response to Taxol, and there are solubility problems in
drug delivery.

Accordingly, there is a need in the art for improved
methods for therapy and diagnosis of breast cancer. The
present invention fulfills these needs and further provides
ADVANTAGES OF THE INVENTION
other related advantages. The animal toxicity bioassay data
Breast cancer is a significant health problem for women in
10 indicated that LD 50 dose for all of the compounds are in the
the United States and throughout the world. Although
range of 250-3000 mg/kg, which is much lower compare to
advances have been made in detection and treatment of the
some of the most promising agents against breast cancer. For
disease, breast cancer remains the second leading cause of
example taxol intra-peritoneal LD 50 dose in mice using the
cancer-related deaths in women, affecting more than 180,
same
bioassay system is 218 mg/kg (JZKEDZ Jun. 1, 1980),
000 women in the United States each year. For women in
North America, the life-time odds of getting breast cancer 15 which is almost a number of magnitude higher then some of
the claimed compounds. Such a low toxicity dose of the
are now one in eight.
compounds claimed gives a strong potential for not to
No vaccine or other universally successful method for the
having such a serious side effects as the most potential drugs
prevention or treatment of breast cancer is currently availof
the present time do. Secondly, more advantages from our
able. The available drugs on the market have a variety of 20
invention are the cheapness and the simplicity of the synstrong side effects, high cost and complicated synthesis. For
thesis of active compounds compare to the present drugs on
example, Taxol is the most promising antitumor agent
the market. The synthesis of claimed compounds from
developed in the past three decades. It was approved by the
commercially available reagents takes four to five synthetic
FDA for the treatment of refractory ovarian cancer in
December, 1992, and was introduced into the marketplace in 25 steps with overall yield in the range of 60--85%. Versus for
example taxol which takes minimum of 40 synthetic steps
January, 1993 by Bristol-Myers Squibb Company (EMS)
with only 2% overall yield, which increases the price of the
operating under a Cooperative Research and Development
compound dramatically.
Agreement (CRADA) with the National Cancer Institute
(NCI). It was approved for the treatment of breast cancer in
Conclusion: Although the invented compounds have not
1994, and is now in transition from second line to first line 30 yet been tested clinically, one can see from the Table 1 that
therapy. Worldwide sales of Taxol reached $1.2 billion in
all of them posses at least 10 times lower acute toxicity
1998. However, Preclinical development continued from
compare to the most promising antitumnor agent developed
1977 until 1983, hampered by a number of obstacles,
in the past three decades, high activity values, ease of
especially the formulation problem. Taxol is highly liposynthesis, and cheap cost. All these advantages provide a
philic and is insoluble in water. Finally, a vehicle consisting 35 potential for the development of new drugs for the prevenof a mixture of Cremophore EL (polyethoxylated caster oil),
tion or treatment of breast cancer.
ethanol and saline was chosen, but its toxicity was a sigWhile the invention has been described, disclosed, illusnificant problem in preclinical studies. The main side effects
trated
and shown in various terms of certain embodiments or
of this drug were found to be congenital malformation in the
fetus and reproductive disorders. The supply of Taxol was 40 modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
also a problem. To obtain Yew bark, the tree had to be killed.
deemed to be, limited thereby and such other modifications
A large Pacific Yew two feet in diameter requires 200 years
or embodiments as may be suggested by the teachings herein
to grow and yields about five pounds of bark. In extractions
are particularly reserved especially as they fall within the
by Polysciences, then the only extraction contractor, a
breadth
and scope of the claims here appended.
0.004% yield of Taxol was obtained. Furthermore, the 45
We claim:
Pacific Yew was a scarce understory tree, and its extinction
1. A compound consisting of 1-(2,4-Dimethyl-phenyl)-2,
and destruction of the old growth forests was threatened by
4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,5-dihydro- lHthe harvest. Few believed, because of the complexity of the
pyrrole-2-carboxylic acid methyl ester.
molecule, that the problem of a commercial supply of Taxol
2. A method of treating breast carcinoma in a human in
could be solved by total synthesis. The first total synthesis 50
need of such treatment comprising the steps of administering
was finally reported in 1994 by the Holton group. Although
to said human, in a systemic, in vitro manner, an anti-tumor
three total syntheses have been subsequently achieved by
effective amount of a compound of claim 1 having the
others, the Holton synthesis is the most efficient, but still
common property of anti-tumor activity against human
requires over 40 steps from camphor and provides an overall
breast
cancer.
yield of approximately 2%.
55
Taxol is perhaps best viewed as an exciting and valuable
lead in cancer chemotherapy. Although Taxol has extended

* * * * *

